NYSE:PKI - PerkinElmer Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$78.00 -0.40 (-0.51 %)
(As of 07/23/2018 08:27 AM ET)
Previous Close$78.40
Today's Range$77.95 - $78.47
52-Week Range$62.43 - $84.49
Volume493,438 shs
Average Volume586,547 shs
Market Capitalization$8.63 billion
P/E Ratio26.90
Dividend Yield0.36%
Beta0.86
PerkinElmer logoPerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and PerkinElmer. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
SymbolNYSE:PKI
CUSIP71404610
Phone781-663-6900

Debt

Debt-to-Equity Ratio0.73
Current Ratio1.33
Quick Ratio0.93

Price-To-Earnings

Trailing P/E Ratio26.90
Forward P/E Ratio21.67
P/E Growth1.79

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales3.82
Cash Flow$3.9235 per share
Price / Cash19.88
Book Value$22.71 per share
Price / Book3.43

Profitability

EPS (Most Recent Fiscal Year)$2.90
Net Income$292.63 million
Net Margins11.73%
Return on Equity13.26%
Return on Assets6.17%

Miscellaneous

Employees11,000
Outstanding Shares110,630,000
Market Cap$8,629.48

PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, July 20th will be given a dividend of $0.07 per share on Friday, August 10th. This represents a $0.28 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date of this dividend is Thursday, July 19th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its earnings results on Monday, April, 30th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.61 by $0.02. The medical research company earned $644 million during the quarter, compared to analysts' expectations of $618.97 million. PerkinElmer had a return on equity of 13.26% and a net margin of 11.73%. PerkinElmer's quarterly revenue was up 0 on a year-over-year basis. During the same period last year, the firm earned $0.55 EPS. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share guidance of $3.60 for the period, compared to the Thomson Reuters consensus estimate of $3.53.

What price target have analysts set for PKI?

12 Wall Street analysts have issued 12 month price objectives for PerkinElmer's shares. Their predictions range from $67.00 to $90.00. On average, they anticipate PerkinElmer's stock price to reach $78.3633 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Ratings for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of PerkinElmer's key competitors?

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman, CEO & Pres (Age 62)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 49)
  • Mr. James Corbett, Exec. VP & Pres of Discovery and Analytical Solutions (Age 55)
  • Mr. Prahlad R. Singh, Exec. VP & Pres of Diagnostics (Age 53)
  • Mr. Frank A. Wilson, Advisor (Age 59)

Has PerkinElmer been receiving favorable news coverage?

News articles about PKI stock have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PerkinElmer earned a daily sentiment score of 0.22 on Accern's scale. They also gave news headlines about the medical research company an impact score of 46.22 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.45%), First National Bank of Omaha (0.12%), Nisa Investment Advisors LLC (0.08%), Smith Graham & Co. Investment Advisors LP (0.06%), Retirement Systems of Alabama (0.05%) and Bank of Montreal Can (0.04%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Frank Anders Wilson, Joel S Goldberg, Kenton J Sicchitano, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer.

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Meag Munich Ergo Kapitalanlagegesellschaft MBH, Fisher Asset Management LLC, Municipal Employees Retirement System of Michigan, Bank of Montreal Can, Hartford Investment Management Co., Prentiss Smith & Co. Inc., Nisa Investment Advisors LLC and Smith Graham & Co. Investment Advisors LP. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Frank Anders Wilson, Nicholas A Lopardo and Peter Barrett. View Insider Buying and Selling for PerkinElmer.

Which major investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including Private Trust Co. NA, Oakbrook Investments LLC, Creative Planning, Xact Kapitalforvaltning AB, Searle & CO., Hudson Valley Investment Advisors Inc. ADV and Sit Investment Associates Inc.. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $78.00.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $8.63 billion and generates $2.26 billion in revenue each year. The medical research company earns $292.63 million in net income (profit) each year or $2.90 on an earnings per share basis. PerkinElmer employs 11,000 workers across the globe.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  350 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  712
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.